Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
18 June 2014Next earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 5 min agoDividend
Analysts recommendations
Institutional Ownership
VRDN Latest News
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported details of its plans to initiate a phase 3 clinical trial program for its SC VRDN-003 product candidate for patients with moderate-to-severe TED. “We are very pleased to have completed a positive Type C meeting with the FDA and to take this next step towards rapidly bringing a hi.
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming investor conferences in June: Jefferies Global Healthcare Conference (New York, NY): Presentation on Wednesday, June 5, 2024, at 5:00 p.m. ET. Goldman Sachs 45th Annual Global Healthcare Conference (Miami, FL).
The mean of analysts' price targets for Viridian Therapeutics, Inc. (VRDN) points to a 97.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $0.86 per share a year ago.
Viridian Therapeutics, Inc. (VRDN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.06 per share a year ago.
There were positive results achieved from Viridian Therapeutics, Inc. phase 1/2 study using VRDN-001 for the treatment of patients with chronic thyroid eye disease. Initiation of the phase 3 THRIVE-2 study, using VRDN-001 for the treatment of patients with chronic thyroid eye disease, is expected by Q3 of 2023. Results from the phase 3 THRIVE-2 study, using VRDN-001 for the treatment of patients with chronic thyroid eye disease, are expected by end of 2024.
Viridian said its lead therapy helped reduce bulging eyes in thyroid eye disease patients. The biotech specializes in rare diseases and immune disorders.
Shares of Viridian Therapeutics Inc. VRDN, +5.06% fell in the extended session Monday after the biotech drug maker said it was making changes to its study design for a chronic thyroid eye disease therapy. Viridian shares fell more than 17% after hours, following a 5.1% rise to close the regular session at $24.52.
Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Louisa Stone - Manager, IR Scott Myers - President and CEO Kristian Humer - Chief Financial and Business Officer Dr. Thomas Ciulla - Chief Development Officer Todd James - SVP, Corporate Affairs and IR Conference Call Participants Derek Archila - Wells Fargo Gavin Clark-Gartner - Evercore ISI Thomas Smith - SVB Securities Laura Chico - Wedbush Securities Kalpit Patel - B. Riley Securities Jason Butler - JMP Securities Rami Katkhuda - LifeSci Operator Welcome to the Viridian Therapeutics First Quarter 2023 Conference Call.
What type of business is Viridian Therapeutics?
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
What sector is Viridian Therapeutics in?
Viridian Therapeutics is in the Healthcare sector
What industry is Viridian Therapeutics in?
Viridian Therapeutics is in the Biotechnology industry
What country is Viridian Therapeutics from?
Viridian Therapeutics is headquartered in United States
When did Viridian Therapeutics go public?
Viridian Therapeutics initial public offering (IPO) was on 18 June 2014
What is Viridian Therapeutics website?
https://www.viridiantherapeutics.com
Is Viridian Therapeutics in the S&P 500?
No, Viridian Therapeutics is not included in the S&P 500 index
Is Viridian Therapeutics in the NASDAQ 100?
No, Viridian Therapeutics is not included in the NASDAQ 100 index
Is Viridian Therapeutics in the Dow Jones?
No, Viridian Therapeutics is not included in the Dow Jones index
When does Viridian Therapeutics report earnings?
The next expected earnings date for Viridian Therapeutics is 08 August 2024